Botensilimab is a next-generation, Fc-enhanced cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitor. It is engineered to not only block the CTLA-4 immune checkpoint like first-generation inhibitors (e.g., ipilimumab) but also to incorporate an Fc domain modified to enhance binding to activating Fc gamma receptors (FcγRs). This design aims to selectively deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment via antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), while simultaneously providing enhanced co-stimulation to effector T cells. It is being investigated in clinical trials (Phase I/II) for the treatment of immunologically "cold" or treatment-refractory advanced solid tumors, both as a monotherapy and in combination with other agents, with the goal of inducing deeper and more durable responses.